Despite the strong evidence in preclinical studies implicating both hyperinsulinemia and DPP4 activity in the pathogenesis of atherosclerosis, multiple large clinical trials of DPP4 inhibitors have failed to demonstrate a reduction in cardiovascular outcomes in individuals with type 2 diabetes mellitus [43]. The gene discussed is DPP4; the disease is atherosclerosis.